Back to News
Market Impact: 0.22
Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Optimi Health plans to begin a Health Canada-authorized Phase 3 trial of synthetic MDMA-assisted therapy for PTSD in 2027. The authorization advances the company's clinical-development pathway, but the long timeline and absence of efficacy or financial data limit the near-term impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
OPTH0.45
More News
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution
- Binance’s $6.3 billion hack raises questions about crypto wallet safety
- DeepSeek Drops Enhanced Coding Agent With Aim to Rival Anthropic
- Crypto industry pours more than $200 million into 2026 midterms to pressure Congress on favorable rules
- France braces for fresh unrest, government vows tough response
- Judge allows NAACP lawsuit over xAI data center pollution to move forward